Glaukos GKOS recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials evaluating its latest approved product, iDose TR. The company also ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results